Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.17 +2.00%

+$0.69 today

Market cap
$6.86B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.91M

Average 1.84M

IMVT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Immunovant, Inc.NASDAQ: IMVT

Stock-Based Compensation · Q2 FY2027 · quarter ended Sep 2026

Stock-based compensation declines year over year

Q2 FY2027 stock-based compensation of $13.28M fell 0.6% year over year, ahead of the -7.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.6% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -0.6% holds above the trailing-twelve-month pace of -7.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$13.28M-3.6% QoQ
Last fiscal yearMar 2026
$55.72M+12.6% YoY
LTMSep 2026
$50.91M-7.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.6%——
1 year+12.6%——
3-year CAGR+19.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2026
55.72M USD
Year-over-year change
+12.6%
4-year CAGR
+12.9%

Stock-Based Compensation vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 stock-based compensation of $50.91M is the 2nd largest of the 11 companies compared; the peer median is $25.6M.
  • Its year-over-year change of -7.8% is the 8th highest of 11, against a peer median of +10.7%.
  • Stock-based compensation amounts to 717.6% of revenue for IMVT, versus a peer median of 13.8%.
IMVT Competitors Peer median
Stock-Based Compensation for IMVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TGTXTG Therapeutics, Inc.LTM Sep 2026$88.18M +44.6%+49.9%9.8%
IMVTImmunovant, Inc.LTM Sep 2026$50.91M -7.8%+19.9%717.6%
ANABAnaptysBio, Inc.LTM Mar 2026$41.12M +24.3%+9.7%17.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$34.28M -12.0%+8.8%—
TRAXFirst Tracks Biotherapeutics IncFY2025$32.3M +20.4%——
ZBIOZenas BioPharma, Inc.LTM Mar 2026$30.16M +97.6%+229.4%—
CABACabaletta Bio, Inc.LTM Mar 2026$21.03M +1.0%+44.8%—
ANNXAnnexon, Inc.LTM Mar 2026$15.5M -21.9%-3.9%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M -2.1%-6.3%144.0%
IMUXImmunic, Inc.LTM Mar 2026$11.29M +44.4%+3.8%—
QTTBQ32 Bio Inc.LTM Mar 2026$3.99M -24.8%+61.9%7.4%
Peer median (excluding IMVT) $25.6M+10.7%+9.7%13.8%

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Depreciation & Amortization126K193K231K377K409K
Deferred Income Tax00000
Stock-Based Compensation34.24M32.3M41.12M49.49M55.72M
Change in Working Capital15.14M(10.85M)2.63M(12.03M)42.06M
Accounts Receivables(11.72M)12.23M(4.56M)2.97M(1.4M)
Inventory00000
Accounts Payables16.25M(17.12M)5.78M10.68M(10.25M)
Other Working Capital10.61M(5.95M)1.41M(25.69M)53.72M
Other Non-Cash Items1.11M1.13M1.13M133K99K
Operating Cash Flow(106.11M)(188.19M)(214.23M)(375.87M)(407.31M)
Capital Expenditures(254K)(197K)(360K)(759K)(8K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(254K)(197K)(360K)(759K)(8K)
Debt Repayment00000
Common Stock Issued129K70.5M472.75M450M596.26M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities200M385K(318K)4.49M(504K)
Financing Cash Flow200.13M70.89M472.43M454.49M595.76M
Effect of Forex Changes(92K)220K993K747K(299K)
Net Change in Cash93.67M(117.29M)258.83M78.61M188.14M
Free Cash Flow(106.37M)(188.39M)(214.59M)(376.63M)(407.32M)

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.